NERV(NERV)
NERV
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|---|
| Revenue Avg | $20M | $56M | $13M | $20M | $150M |
| Low | $20M | $56M | $13M | $20M | $150M |
| High | $20M | $56M | $13M | $20M | $150M |
| EBITDA Avg | — | — | — | — | — |
| Low | — | — | — | — | — |
| High | — | — | — | — | — |
| EBIT Avg | — | — | — | — | — |
| Low | — | — | — | — | — |
| High | — | — | — | — | — |
| Net Income Avg | $-30M | $-6M | $-7M | $-4M | $592,480 |
| Low | $-30M | $-6M | $-7M | $-4M | $592,480 |
| High | $-30M | $-6M | $-7M | $-4M | $592,480 |
| EPS Avg | $-3.54 | $-0.69 | $-0.83 | $-0.42 | $0.07 |
| Low | $-3.54 | $-0.69 | $-0.83 | $-0.42 | $0.07 |
| High | $-3.54 | $-0.69 | $-0.83 | $-0.42 | $0.07 |
| Analysts (Rev / EPS) | 3 / 1 | 3 / 1 | 3 / 1 | 2 / 1 | 1 / 1 |
| Metric | Q2 2026 | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|---|
| Revenue Avg | — | — | — | — | — | — | — |
| Low | — | — | — | — | — | — | — |
| High | — | — | — | — | — | — | — |
| EBITDA Avg | — | — | — | — | — | — | — |
| Low | — | — | — | — | — | — | — |
| High | — | — | — | — | — | — | — |
| EBIT Avg | — | — | — | — | — | — | — |
| Low | — | — | — | — | — | — | — |
| High | — | — | — | — | — | — | — |
| Net Income Avg | $-8M | $-9M | $-9M | $-8M | $-9M | $-5M | $-5M |
| Low | $-8M | $-9M | $-9M | $-8M | $-9M | $-5M | $-5M |
| High | $-8M | $-9M | $-9M | $-8M | $-9M | $-5M | $-5M |
| EPS Avg | $-0.19 | $-0.21 | $-0.21 | $-0.19 | $-0.20 | $-0.12 | $-0.11 |
| Low | $-0.19 | $-0.21 | $-0.21 | $-0.19 | $-0.20 | $-0.12 | $-0.11 |
| High | $-0.19 | $-0.21 | $-0.21 | $-0.19 | $-0.20 | $-0.12 | $-0.11 |
| Analysts (Rev / EPS) | — / 1 | — / 1 | — / 1 | — / 1 | — / 1 | — / 1 | — / 1 |